Exagen Q3 2026 Results: Net Loss of $6.34M, Loss Narrows
Exagen Inc. reported revenue of $18.4 million for Q3 2026, a 6.8% increase year-over-year, while narrowing its net loss to $6.3 million compared to $7.1 million in Q3 2025. The company strengthened its capital position through $6.4 million in net proceeds from an at-the-market (ATM) equity offering during the quarter.
- Key figure
- Net loss $6.34M